Fig. 1

ANP32B is upregulated in AML and correlated with poor clinical characteristics. A The ChIP-Seq data demonstrates H3K27ac signaling of ANP32B in AML and B-ALL clinical samples, while Hi-C data analysis reveals interactions between super-enhancer regions and the promoter of ANP32B in AML cells. B Super-enhancer profiling in AML sample. Enhancers were ranked by increasing H3K27ac signal in AML sample. Number of super-enhancers identified in AML sample is shown. ANP32B which is associated with super-enhancer in AML sample is shown. C ANP32B was highly expressed in AML compared to healthy control according to a public transcriptomic dataset (GSE114868). D Western blot assay for ANP32B protein expression in leukemia cell lines. E The Kaplan–Meier survival curve from the R2 database (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi)